Procter & Gamble will acquire supplement manufacturer Thorne for $3.8 billion, it was announced Aug. 4. The deal represents a spectacular 77% rate of return on the investment for the brand’s current owner.
The acquisition marks a significant moment for the health and wellness industry, with consumer packaged goods giant Procter & Gamble (P&G) strategically expanding its footprint into the high-growth premium supplement market. The deal, expected to close later this year pending regulatory approvals, positions Thorne, a long-standing name in science-backed supplements, under the umbrella of P&G’s growing health care portfolio, which already includes established brands such as Align Probiotic and Metamucil, as well as the natural products stalwart New Chapter. This move underscores P&G’s commitment to investing in consumer health and proactive wellness solutions.
Thorne, founded over 40 years ago in the Pacific Northwest by Al Czap, has cultivated a reputation for quality and scientific rigor. For many years, the company was headquartered in Sandpoint, Idaho, a picturesque community known for its natural beauty. The brand’s journey has been one of continuous evolution, driven by a commitment to product integrity and expanding its market reach.
A pivotal moment in Thorne’s recent history occurred in 2018 when, under the leadership of former CEO Paul Jacobsen, the company undertook a significant operational expansion. It relocated to a purpose-built, 240,000-square-foot manufacturing facility in Summerville, South Carolina. This relocation coincided with a strategic pivot, moving beyond its traditional base in the practitioner channel to embrace retail supplement sales and consumer health testing. This diversification proved to be a catalyst for substantial growth and market penetration.
The strategic shift and operational advancements were validated when Thorne went public in 2021, achieving a valuation of $525 million. The company’s trajectory continued upward, leading to a private equity acquisition in 2023. L. Catterton, a prominent private equity firm specializing in consumer brands, took Thorne private once again in a transaction valued at $680 million. Following this acquisition, Colin Watts, former CEO of The Vitamin Shoppe, was appointed to lead Thorne, bringing extensive retail and consumer-facing experience to the helm. Thorne’s projected full-year revenue for 2025 is anticipated to exceed $500 million, a testament to its sustained growth and market appeal.
The Impact of Private Equity on Thorne’s Ascent
The narrative of Thorne’s recent growth serves as a compelling case study in the strategic benefits that private equity ownership can bring to a brand. Scott Steinford, CEO of PreMark Health Sciences, a Texas-based contract manufacturer with extensive experience in guiding brands through acquisition phases, commented on Thorne’s evolution. "Everybody bitches about what private equity firms do when they buy a brand like this," Steinford told SupplySide Supplement Journal. "But not every private equity transaction is a detriment. This brand emerged from the practitioner channel where it was largely under the radar to a large retail brand in a very short time. That came as a result of aggressive and expansionist thinking."
Steinford’s perspective highlights how strategic investment and decisive leadership can accelerate a brand’s market presence. Thorne’s transition from a practitioner-focused entity to a widely recognized consumer brand in a relatively short period is attributed to this forward-thinking approach. From a financial and strategic standpoint, Thorne represented an attractive acquisition target not only due to its impressive recent performance but also because of its positioning within a market sector poised for continued robust expansion.
The increasing consumer focus on proactive health and wellness, often referred to as the "wellness revolution," has driven significant market demand for supplements and nutritional products. Steinford further elaborated on this trend, stating, "It reinforces the fact that proactive healthcare is coming to the forefront in our healthcare system. This provides proof that the idea is becoming known worldwide." This macro trend provides a fertile ground for companies like Thorne, and its acquisition by a CPG behemoth like P&G suggests a recognition of this enduring market shift.
A Precedent Set by New Chapter Under P&G’s Stewardship
The success of Thorne under P&G’s potential ownership is often viewed through the lens of P&G’s prior acquisition of New Chapter, another prominent natural supplement brand. Marc Brush, a seasoned industry strategy consultant and former editor of the Informa publication Nutrition Business Journal, believes that New Chapter’s experience under corporate ownership provides a positive outlook for Thorne’s future growth opportunities.
P&G acquired New Chapter in 2012. While there were initial reports of friction between P&G management and New Chapter founders Paul and Barbi Schulick, leading to their departure from management roles in 2018, the overall trajectory of the brand under P&G has been largely viewed as successful by industry observers. Paul Schulick, in a past interview, expressed concerns about potential pressure to cut corners for profit, a common apprehension when legacy natural brands are integrated into large CPG structures. However, many industry analysts, including Brush, have given P&G high marks for its management of New Chapter.
"The New Chapter acquisition happened way back in 2012, which is plenty of time for most Big CPG companies to screw things up," Brush remarked. "I think New Chapter has performed well, all things considered, under the P&G banner and that gives them confidence to place another bet this big." This sentiment suggests that P&G has learned from its past integrations and has developed a more nuanced approach to managing distinct brand equities within its portfolio.
Analyzing the Premium Valuation and Future Potential
The substantial $3.8 billion valuation for Thorne reflects not only its current market standing but also significant expectations for future growth. Brush speculated that P&G’s willingness to pay such a premium is a dual bet: on the sustained expansion of the supplement category and on the robust, professional foundation that Thorne’s various leadership teams have meticulously built over its history.
Thorne’s projected 2026 sales of $650 million, according to Brush’s analysis, place the P&G offer at a "super frothy" multiple of approximately 5.8 times revenue. While this multiple might appear high by historical M&A standards, Brush suggests that if Thorne’s anticipated future growth materializes, the deal could quickly align with more conventional valuation norms.
"The return to L Catterton is impressive, but this was years in the making," Brush stated. "Thorne built itself on quality in its first chapter under Al Czap, then grounded the company in high science in the Paul Jacobson era, and now they’ve cracked the code with consumers online with Colin Watts and his team." This breakdown highlights Thorne’s multifaceted evolution: from its foundational commitment to quality, through its embrace of scientific research, to its recent success in direct-to-consumer channels.
Brush emphasized that the premium price is largely tied to Thorne’s demonstrated ability to transition effectively from its origins in the practitioner and clinic channels to thriving in the highly competitive online retail space, including platforms like Amazon. "Few brands can chart the transition from clinics and practitioners to Amazon and consumers as well as Thorne has, and this gives P&G confidence that the road to $1 billion in annual revenues for Thorne is possible," he added. This mastery of omnichannel distribution and consumer engagement is a critical factor in P&G’s strategic calculus.
The success Thorne has experienced in online sales is likely a major driver behind P&G’s decision to make such a significant investment. In an era where digital commerce is paramount, Thorne’s proven ability to connect with and convert consumers online offers a powerful advantage.
Navigating the Challenges of Post-Acquisition Integration
While the history of large corporations acquiring innovative smaller brands is replete with cautionary tales of integration failures, Brush expressed optimism regarding P&G’s potential to succeed with Thorne. "Most of these marquee deals go south over time, which is why that New Chapter precedent is so important," he explained. "I would say that P&G has done a better job than most at maintaining the real brand equity of their acquisitions in supplements, but it will still be a challenge. At these prices, Thorne will have to keep growing fast, and the daily decisions that companies make to protect quality and trust are tough to defend over time."
The key challenge for P&G will be to maintain Thorne’s core values of quality, scientific integrity, and consumer trust while leveraging P&G’s vast resources for scaling and distribution. The premium valuation necessitates continued high growth, which in turn places pressure on operational efficiency and strategic decision-making. Upholding the stringent quality standards that have defined Thorne, especially in the context of increasing production volume and market demand, will be paramount to long-term success.
The partnership between Thorne and WNBA star Napheesa Collier, who champions Thorne’s NSF Certified for Sport products, exemplifies the brand’s commitment to athlete-level quality and transparency. Such endorsements, combined with Thorne’s existing scientific credibility, form the bedrock of its brand equity. P&G’s task will be to nurture and expand upon this equity without compromising the very attributes that made Thorne so attractive in the first place. The integration process will be closely watched by industry observers as a barometer for the future of strategic acquisitions in the burgeoning health and wellness sector.
